携带初治EGFR或KRAS共突变的ALK阳性非小细胞肺癌患者接受酪氨酸激酶抑制剂治疗的临床结局
该研究分析了来自瑞士六家中心的14例转移性非小细胞肺癌患者,这些患者经FISH检测ALK重排且测序检测到EGFR或KRAS共突变。结果显示,ALK/KRAS共突变患者中7例有6例(86%)对克唑替尼原发耐药;ALK/EGFR共突变患者接受ALK和EGFR酪氨酸激酶抑制剂的结局似乎劣于单一突变患者的预期,但需进一步研究明确哪些患者仍可从相应TKI中获益。
要点
- ALK/KRAS共突变患者中,7例有6例(86%)对克唑替尼原发耐药。
- ALK/EGFR共突变患者接受克唑替尼的疗效不一,部分出现部分缓解。
- ALK/EGFR共突变患者接受EGFR TKI的中位无进展生存期为5.8个月(范围3.0-6.9个月)。
核心结论
- 初治ALK/KRAS共突变与8例患者中7例对ALK TKI治疗耐药相关。
- ALK/EGFR共突变患者接受ALK和EGFR TKI的结局似乎劣于单一突变患者的预期,但需进一步研究明确哪些患者仍可从相应TKI中获益。
研究设计与样本
- 研究分析了来自瑞士六家中心的14例转移性非小细胞肺癌患者,这些患者经荧光原位杂交检测ALK重排且经测序检测EGFR或KRAS共突变。
主要发现
- 共识别14例腺癌患者,其中5例为ALK/EGFR共突变,9例为ALK/KRAS共突变。
- ALK/KRAS共突变患者中,7例有6例(86%)对克唑替尼原发耐药;1例患者疾病稳定持续26个月。
- ALK/EGFR共突变患者中,1例接受克唑替尼治疗1.3个月后立即进展,2例分别获得5.7个月和7.3个月的部分缓解。
- 4例接受EGFR TKI治疗的ALK/EGFR共突变患者中,3例在不同治疗线数中至少获得一次缓解:4例患者获得部分缓解,其中3例使用阿法替尼,1例使用奥希替尼。
- 1例患者使用奥希替尼获得完全缓解,1例患者对厄洛替尼原发耐药;首次EGFR TKI治疗的中位无进展生存期为5.8个月(范围3.0-6.9个月)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: NSCLC with de novo anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements and EGFR or KRAS mutations co-occur very rarely. Outcomes with tyrosine kinase inhibitors (TKIs) in these patients are poorly understood. METHODS: Outcomes of patients with metastatic NSCLC de novo co-alterations of ALK/EGFR or ALK/KRAS detected by fluorescence in situ hybridization (ALK) and sequencing (EGFR/KRAS) from six Swiss centers were analyzed. RESULTS: A total of 14 patients with adenocarcinoma were identified. Five patients had ALK/EGFR co-alterations and nine had ALK/KRAS co-alterations. Six of seven patients with ALK/KRAS co-alterations (86%) were primary refractory to crizotinib. One patient has had ongoing disease stabilization for 26 months. Of the patients with ALK/EGFR co-alterations, one immediately progressed after receiving crizotinib for 1.3 months and two had a partial response for 5.7 and 7.3 months, respectively. Three of four patients with ALK/EGFR co-alterations treated with an EGFR TKI achieved one or more responses in different lines of therapy: four patients had a partial response, three with afatinib and one with osimertinib. One patient achieved a complete remission with osimertinib, and one patient was primary refractory to erlotinib. Median PFS during treatment with a first EGFR TKI was 5.8 months (range 3.0-6.9 months). CONCLUSIONS: De novo concurrent ALK/KRAS co-alterations were associated with resistance to ALK TKI treatment in seven out of eight patients. In patients with ALK/EGFR co-alterations, outcomes with ALK and EGFR TKIs seem inferior to what would be expected in patients with either alteration alone, but further studies are needed to clarify which patients with ALK/EGFR co-alterations may still benefit from the respective TKI.
引用
- Schmid S, Gautschi O, Rothschild S, et al. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol. 2016. PMID: 28007627. doi:10.1016/j.jtho.2016.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。